Tri Locum Partners LP
In its 13F for Q1 2026 (holdings as of March 31, 2026, filed May 18, 2026), Tri Locum Partners LP reported 17 stock positions worth $712.5 million. Its top holding was Johnson & Johnson (JNJ) at 14.2% of the portfolio, followed by Intuitive Surgical (ISRG, 9.9%) and Thermo Fisher Scientific (TMO, 9.1%). Compared with Q4 2025, it opened 6 new positions, sold out of 4, added to 3 and reduced 8. The biggest buy was a new position in Intuitive Surgical (ISRG) and the biggest sale an exit from Danaher (DHR).
- Most Recent 13F
- Q2 2026
- Location
- NEW YORK, NY
- CIK
- 0001826434
- Portfolio Value
- $712.5M (Q1 2026)
- SEC Filing
- 0001826434-26-000004 ↗ filed May 18, 2026
Holdings Value
Holdings 17 stocks · $712.5M
| JNJ Johnson & Johnson | 14.22% | 414,503 | $101.3M | Reduce -31.3% |
| ISRG Intuitive Surgical Inc. | 9.91% | 153,250 | $70.6M | New |
| TMO Thermo Fisher Scientific Inc. | 9.13% | 132,413 | $65.1M | New |
| ASND Ascendis Pharma A/S | 8.20% | 255,332 | $58.4M | Reduce -3.6% |
| VRTX Vertex Pharmaceuticals Inc. | 8.10% | 129,314 | $57.7M | New |
| LLY Eli Lilly & Co. | 7.98% | 61,795 | $56.8M | Reduce -2.4% |
| MDGL Madrigal Pharmaceuticals Inc. | 7.59% | 103,288 | $54.1M | Add +20.1% |
| DXCM Dexcom Inc. | 6.15% | 698,158 | $43.8M | Add +65.6% |
| UTHR United Therapeutics Corp. | 5.86% | 70,370 | $41.7M | Reduce -41.8% |
| NUVL Nuvalent Inc. Class A | 4.44% | 308,506 | $31.6M | Add +0.4% |
| TEVA Teva Pharmaceutical-SP ADR | 4.32% | 1,021,008 | $30.8M | Reduce -28.9% |
| JAZZ Jazz Pharmaceuticals PLC | 4.21% | 158,663 | $30.0M | New |
| ARGX Argenx SE - ADR | 3.24% | 31,635 | $23.1M | Reduce -16.0% |
| TARS Tarsus Pharmaceuticals Inc. | 2.49% | 252,588 | $17.7M | New |
| DNTH Dianthus Therapeutics Inc. | 1.71% | 145,543 | $12.2M | Reduce -76.6% |
| AXSM Axsome Therapeutics Inc. | 1.47% | 62,116 | $10.5M | Reduce -69.2% |
| DFTX Definium Therapeutics Inc. | 0.98% | 369,588 | $7.0M | New |
Portfolio Sells Q4 2025 → Q1 2026
| DHR Danaher Corp. | Sold out | 0.00% | −10.31 |
| BSX Boston Scientific Corp. | Sold out | 0.00% | −6.44 |
| IONS Ionis Pharmaceuticals Inc. | Sold out | 0.00% | −5.72 |
| VERA Vera Therapeutics Inc. | Sold out | 0.00% | −5.30 |
| AXSM Axsome Therapeutics Inc. | Reduce -69.2% | 1.47% | −3.31 |
| JNJ Johnson & Johnson | Reduce -31.3% | 14.22% | −1.99 |
| UTHR United Therapeutics Corp. | Reduce -41.8% | 5.86% | −1.79 |
| DNTH Dianthus Therapeutics Inc. | Reduce -76.6% | 1.71% | −1.62 |
| TEVA Teva Pharmaceutical-SP ADR | Reduce -28.9% | 4.32% | −1.50 |
| ARGX Argenx SE - ADR | Reduce -16.0% | 3.24% | −0.87 |
| LLY Eli Lilly & Co. | Reduce -2.4% | 7.98% | −0.85 |
| ASND Ascendis Pharma A/S | Reduce -3.6% | 8.20% | +0.86 |
Portfolio Buys Q4 2025 → Q1 2026
| ISRG Intuitive Surgical Inc. | New | 9.91% | +9.91 |
| TMO Thermo Fisher Scientific Inc. | New | 9.13% | +9.13 |
| VRTX Vertex Pharmaceuticals Inc. | New | 8.10% | +8.10 |
| JAZZ Jazz Pharmaceuticals PLC | New | 4.21% | +4.21 |
| DXCM Dexcom Inc. | Add +65.6% | 6.15% | +2.52 |
| TARS Tarsus Pharmaceuticals Inc. | New | 2.49% | +2.49 |
| MDGL Madrigal Pharmaceuticals Inc. | Add +20.1% | 7.59% | +1.08 |
| DFTX Definium Therapeutics Inc. | New | 0.98% | +0.98 |
| NUVL Nuvalent Inc. Class A | Add +0.4% | 4.44% | +0.42 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 19 | $813.2M | JNJ, VRTX, LLY, ASND, DXCM |
| Q1 2026 | 17 | $712.5M | JNJ, ISRG, TMO, ASND, VRTX |
| Q4 2025 | 15 | $770.1M | JNJ, DHR, LLY, UTHR, ASND |
| Q3 2025 | 18 | $435.1M | JNJ, UTHR, MRK, AXSM, ASND |
| Q2 2025 | 23 | $329.5M | TEVA, MDGL, ALNY, ARGX, ASND |
| Q1 2025 | 22 | $194.9M | CI, MCK, SLNO, TEVA, INSP |
| Q4 2024 | 28 | $482.7M | TEVA, ZBH, ARGX, NTRA, INSP |
| Q3 2024 | 20 | $417.4M | PFE, TEVA, NTRA, STVN, ARGX |
| Q2 2024 | 25 | $395.5M | TEVA, ARGX, ASND, AMGN, NTRA |
| Q1 2024 | 27 | $288.4M | TEVA, AVDL, SILK, NTRA, ASND |